Investment Rating - The report maintains a positive investment rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming compared to the ChiNext and CSI 300 indices, ranking 17th among all industries [2][36] - The report emphasizes the importance of innovation, international expansion, and overcoming challenges as key themes for investment in 2026, with a focus on BD 2.0, small nucleic acids, and supply chain opportunities [3][4] - The upcoming adjustment of the National Essential Drug List is seen as critical, aiming to address clinical needs that have evolved since the last update in 2018, particularly in pediatrics, oncology, and rare diseases [5][14] Summary by Sections National Essential Drug List Adjustment Analysis - The current drug list has not been updated since 2018, leading to a disconnect with clinical needs, necessitating a systematic adjustment [14] - The adjustment will focus on filling gaps in disease coverage, particularly in pediatrics, oncology, and rare diseases, while also solidifying the integration of collective procurement and national negotiation outcomes [18][19] - The report identifies potential beneficiaries in traditional Chinese medicine, particularly in areas with previously weak coverage [28] JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline advancements and key clinical milestones for 2026 [33] - Companies like Pfizer, Merck, and Eli Lilly presented their focus on innovative treatments and upcoming clinical trials, indicating a robust pipeline for future growth [34][35] Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance in early 2026 has shown a 7.08% increase, outperforming both the CSI 300 and ChiNext indices [36] - The report notes a shift in market sentiment, with certain innovative sectors like AI healthcare and medical robotics showing strong performance, while traditional sectors faced adjustments [2][3]

Core Viewpoint - The article highlights the ongoing reform of drug package inserts to make them more accessible for elderly patients, with a focus on the successful implementation by Inner Mongolia Kang En Bei Pharmaceutical Co., Ltd. [1][6] Group 1: Company Initiatives - Inner Mongolia Kang En Bei has completed the elderly-friendly reform of its drug, Shexiang Tongxin Dropping Pills, which has been officially launched in October [1][6] - The company currently produces 110,000 boxes of Shexiang Tongxin Dropping Pills daily, with the new package inserts set to cover major sales networks and medical institutions nationwide [6] Group 2: Industry Trends - The reform of drug package inserts is part of a national policy initiative aimed at improving medication accessibility for elderly patients, with a focus on simplifying complex medical terminology [1][5] - The new version of the package insert has reduced the number of sections from 18 to 9, emphasizing essential information such as "indications," "dosage," "contraindications," and "precautions" [2][5] - The ongoing reform is expected to deepen by 2025, with more user-friendly package inserts being introduced to enhance medication safety and understanding for elderly patients [6]